Viatris has completed its acquisition of Pacira BioSciences, expanding its U.S. innovative medicines business and establishing a larger position in non-opioid pain management.
The transaction, originally announced on October 8, 2026, was completed through a cash tender offer followed by a merger.
Viatris offered Pacira shareholders $36.50 in cash for each outstanding share, before applicable withholding taxes and without interest.
The tender offer expired one minute after 11:59 p.m. Eastern Time on November 16. Approximately 32.9 million shares were validly tendered and not withdrawn, representing about 66.46% of Pacira’s outstanding shares.
After the tender conditions were satisfied or waived, Peach Purchaser Sub, a wholly owned Viatris subsidiary, accepted the shares for payment.
Pacira Becomes A Wholly Owned Viatris Subsidiary
Following the tender offer, Peach Purchaser Sub merged into Pacira under Section 251(h) of Delaware’s corporate law.
That provision permits certain acquisitions to proceed without a separate shareholder vote after a qualifying tender offer meets the required conditions.
Pacira continued as the surviving company and became a wholly owned Viatris subsidiary. Shares that were not tendered were converted into the right to receive the same $36.50-per-share cash consideration.
Pacira’s shares will be delisted from the Nasdaq Global Select Market following completion of the transaction.
The acquisition adds Pacira’s non-opioid pain-management products and expertise to Viatris’ portfolio. Viatris said the businesses have complementary products and capabilities that can support a leadership position in the market.
Non-opioid pain management has attracted greater attention as healthcare providers seek approaches that can control pain while reducing reliance on opioid medications. Actual treatment decisions depend on the patient, procedure, clinical evidence, approved labeling, and physician judgment.
Acquisition Expected To Add Up To $100 Million In 2026 Revenue
Viatris expects the acquisition to contribute between $90 million and $100 million in revenue during the period from November 17 through December 31, 2026.
This is a company forecast and remains subject to operating performance and other factors during the post-acquisition period.
The transaction is part of Viatris’ strategy to strengthen its innovative medicines business in the United States. The company maintains a broader portfolio spanning generics, established brands, value-added medicines, and innovative therapies.
Integrating Pacira gives Viatris additional commercial, medical, and operational capabilities in pain management. It also adds employees with specialized experience in developing and marketing non-opioid products.
The closing completes the ownership transfer, but Viatris will still need to integrate Pacira’s personnel, products, operations, and systems. Successful integration will influence the acquisition’s longer-term financial and strategic impact.
Viatris is headquartered in the United States and maintains global centers in Pittsburgh, Shanghai, and Hyderabad, India.
KEY QUOTE:
Today marks an important milestone in the execution of our strategy to strengthen our U.S. innovative medicines business. With Pacira now part of Viatris, we are bringing together complementary portfolios, capabilities and expertise to establish a leadership position in non-opioid pain management. We are excited to welcome our new Pacira colleagues as we create new opportunities to make a meaningful difference for patients and accelerate our path to sustained revenue and earnings growth.
Scott A. Smith, CEO of Viatris

